nex-z三期临床试验出现严重不良事件 Intellia(NTLA.US)股价暴跌超40%

Core Viewpoint - Intellia Therapeutics (NTLA.US) experienced a significant stock price drop of 47.6% during trading, closing down 42.23% due to the suspension of two Phase 3 clinical trials for nexiguran ziclumeran (nex-z) following a serious adverse event report [1] Group 1: Clinical Trials - The suspension of the trials was prompted by a report of a serious adverse event in the MAGNITUDE trial, where a patient was hospitalized due to grade 4 liver transaminase elevation and increased total bilirubin [1] - The MAGNITUDE trial is designed to evaluate the efficacy and safety of nex-z for treating transthyretin amyloid cardiomyopathy (ATTR-CM) [1] - The second suspended trial, MAGNITUDE-2, focuses on transthyretin amyloid polyneuropathy (ATTR-PN) [1] Group 2: Patient Enrollment - Patient enrollment for both trials has been paused, with the MAGNITUDE trial having enrolled 650 patients and MAGNITUDE-2 enrolling 47 patients to date [1] - It is estimated that over 450 patients have received treatment with nex-z [1]